These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 16643415

  • 1. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM.
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [Abstract] [Full Text] [Related]

  • 2. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
    Hondeghem LM.
    Novartis Found Symp; 2005 Mar; 266():235-44; discussion 244-50. PubMed ID: 16050272
    [Abstract] [Full Text] [Related]

  • 3. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E, Watson T, Lip GY.
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [Abstract] [Full Text] [Related]

  • 4. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA, Mönnig G, Osada N, Breithardt G, Haverkamp W, Eckardt L.
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [Abstract] [Full Text] [Related]

  • 5. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K, Dorian P.
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [Abstract] [Full Text] [Related]

  • 6. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
    Shah RR, Hondeghem LM.
    Heart Rhythm; 2005 Jul; 2(7):758-72. PubMed ID: 15992736
    [Abstract] [Full Text] [Related]

  • 7. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W.
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [Abstract] [Full Text] [Related]

  • 8. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
    Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, Zankov DP, Toyoda F, Matsuura H, Horie M, Sunagawa K.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):300-7. PubMed ID: 15653031
    [Abstract] [Full Text] [Related]

  • 9. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):229-39. PubMed ID: 17054943
    [Abstract] [Full Text] [Related]

  • 10. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
    Hondeghem LM.
    Drug Saf; 2018 Jan 28; 41(1):11-17. PubMed ID: 28853038
    [Abstract] [Full Text] [Related]

  • 11. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Jan 28; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 12. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR, Yan GX, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2013 Jan 28; 68(2):250-259. PubMed ID: 23337247
    [Abstract] [Full Text] [Related]

  • 13. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP.
    Fundam Clin Pharmacol; 2004 Apr 28; 18(2):139-51. PubMed ID: 15066127
    [Abstract] [Full Text] [Related]

  • 14. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL, Lau YS, Teo WS.
    Singapore Med J; 2001 Dec 28; 42(12):566-70. PubMed ID: 11989578
    [Abstract] [Full Text] [Related]

  • 15. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH, Wilson LD, Jeyaraj D, Fossa AA, Rosenbaum DS.
    J Cardiovasc Pharmacol; 2012 Aug 28; 60(2):165-71. PubMed ID: 22561361
    [Abstract] [Full Text] [Related]

  • 16. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM.
    Acta Cardiol; 2008 Feb 28; 63(1):1-7. PubMed ID: 18372573
    [Abstract] [Full Text] [Related]

  • 17. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL, Kung MF.
    Pharmacoepidemiol Drug Saf; 2009 Mar 28; 18(3):235-9. PubMed ID: 19145580
    [Abstract] [Full Text] [Related]

  • 18. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
    Gallacher DJ, Van de Water A, van der Linde H, Hermans AN, Lu HR, Towart R, Volders PG.
    Cardiovasc Res; 2007 Nov 01; 76(2):247-56. PubMed ID: 17669388
    [Abstract] [Full Text] [Related]

  • 19. Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts.
    Hondeghem LM.
    Prog Biophys Mol Biol; 2016 May 01; 121(1):3-10. PubMed ID: 26980523
    [Abstract] [Full Text] [Related]

  • 20. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
    Fazekas T, Liszkai G.
    Orv Hetil; 2005 Mar 06; 146(10):451-60. PubMed ID: 15835343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.